Why the fifth week of a mazdutide dose feels different from the first
The exposure curve explains the timing of both the benefit and the side effects. It is almost never shown to the person injecting.
Yuki Morishita
Page 3 of 8 of this archive, newest first.
Archive — page 3
142 piecesForty-four per cent: reading the nausea figure properly
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
FLOW extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why "muscle-sparing" is a marketing term and not a measurement
A tour of the source literatures, with an assessment of how far each legitimately reaches.
What TRIUMPH-1 tells us about maintenance, and what it does not
Dose reduction is not withdrawal, and the trials that tested withdrawal cannot be read as testing it.
Every fortnight, every third week, seasonally: an unstudied practice
What the exposure arithmetic says about a fortnightly schedule, and where the arithmetic stops being informative.
Eating enough protein on a suppressed appetite is an arithmetic problem before it is a nutritional one
A survey of what the meta-analyses support, with the populations named.
There is no discontinuation syndrome, and that changes the argument
The best argument for tapering is behavioural rather than pharmacological, and it deserves to be made on its own terms.
A supply gap is a pharmacological event
Concentrations fall by half a week, so a month away leaves a small fraction of steady state. Resuming at the previous dose presents the receptor with a step it has not seen…
LEADER misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The tolerability data everybody quotes and nobody reads
Severity in these tables is graded by interference with activity, not by how unpleasant the experience was. Those are different measurements.
SELECT misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The advice is mostly reasonable. The certainty is not earned.
The gap between a defensible recommendation and a confident one is where most of the harm in this subject lives.
Grams per kilogram of what? The denominator problem in protein guidance
A survey of what the meta-analyses support, with the populations named.
SURMOUNT-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The out-of-range flag is a statistical convention with a printer attached
A flag is a probability statement about a population. It is not a statement about the person holding the printout.
Antiemetics, laxatives and the thin literature underneath them
Constipation is the most tractable of the effects and the most consistently under-managed.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A year after stopping: what the trials found at the far end
Fat mass, lean mass, and the composition of regained weight — the thinnest literature in this piece.